Statins and amyotrophic lateral sclerosis - The level of evidence for an association

Journal of Internal Medicine

Volumn 266, Issue 6, 2009, Pages 520-526

  Toft Sorensen H ^a,b   Lash, T L ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Spontaneous reporting; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SURVEILLANCE PROGRAM; FATTY LIVER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INCIDENCE; MEDLINE; MOTOR NEURON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENESCENCE; WORLD HEALTH ORGANIZATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 70449417612     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02173.x     Document Type: Review

References (44)

1. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1998 319 : 24 33.
2. Insull W. The pathology of atheroschlerosis: plaque development and plaque responses to medical treatment. Am J Med 2009 122 : S3 14.
3. Okazaki S, Yokoyama T, Miyauchi K et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004 110 : 1061 1068.
4. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol and regression of coronary atherosclerosis. JAMA 2007 297 : 499 508.
5. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) Collaborators, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
6. Corti R, Fuster V, Fayad ZA et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blinded trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005 46 : 106 112.
7. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006 166 : 2307 2313.
8. Bavry AA, Mood GR, Kumbhani DJ, Borek PP, Askari AT, Bhatt DL. Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials. Am J Cardiovasc Drugs 2007 7 : 135 141.
9. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001 357 : 1063 1068.
10. Newby LK, Kristinsson A, Bhapkar MV et al. SYMPHONY and 2nd SYMPHONY Investigators. Sibrafiban vs aspirin to yield maximun protection from ischemic heart events post-acute coronary syndromes. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002 287 : 3087 3095.
11. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA 2002 287 : 3130 3132.
12. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001 285 : 1711 1718.
13. Briel M, Schwartz GG, Thompson PL et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006 295 : 2046 2056.
14. Armitage J. The safety of statins in clinical practice. Lancet 2007 370 : 1781 1790.
15. Ray JG. Do we care if statins prevent venous thromboembolism? J Thromb Haemost 2004 2 : 695 696.
16. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005 25 : 287 294.
17. Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action. J Thromb Haemost 2006 4 : 1925 1927.
18. Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versius ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005 111 : 2356 2363.
19. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004 109 : II42 8.
20. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotopic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004 94 : 497 500.
21. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 1996 14 : 11 24.
22. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007 17 : 194 200.
23. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008 337 : 1159 1162.
24. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006 97 (suppl 8A 52C 60C.
25. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006 97 (suppl 8A 6C 26C.
26. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001 12 : 565 569.
27. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007 195 : 7 16.
28. Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet 2007 369 : 2031 2041.
29. Fang F, Valdimarsdóttir U, Bellocco R et al. Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol 2009 66 : 515 519.
30. Forbes RB, Colville S, Swingler RJ, Scottish ALS/MND Register. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing 2004 33 : 131 134.
31. Cutler RG, Pedersen WA, Carmandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol 2002 52 : 448 457.
32. Albert SM. Dyslipidemia in ALS - Good, bad or unclear? Neurology 2008 70 : 988 989.
33. Dupuis L, Corcia P, Fergani A et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 2008 70 : 1004 1009.
34. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 2007 30 : 515 525.
35. Colman E, Szarfman A, Wyeth J et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiol Drug Saf 2008 17 : 1068 1076.
36. Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009 32 : 649 661.
37. Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotropic lateral sclerosis. J Neurol Sci 2008 273 : 81 3.
38. Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medication safe in patients with ALS? Amyotroph Lateral Scler 2008 9 : 223 228.
39. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004 13 : 519 523.
40. Greenland S, Lash TL. Bias analysis. In : KJ Rothman, S Greenland, TL Lash. Modern Epidemiology. Philadelphia, PA, USA : Lippincott Williams Wilkins, 2008 345 380.
41. Greenland S, O'Rourke K. Meta-analysis. In : KJ Rothman, S Greenland, TL Lash. Modern Epidemiology. Philadelphia, PA, USA : Lippincott Williams Wilkins, 2008 652 682.
42. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006 44 : 1075 1082.
43. Riahi S, Fonager K, Toft E et al. Use of lipid-lowering drugs during 1991-98 in Northern Jutland, Denmark. J Clin Pharmacol 2001 52 : 308 311.
44. Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990-1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997 53 : 185 189.